A Phase II multicenter, placebo-controlled, proof-of-concept study evaluating the safety, and efficacy of intratympanic STR001 thermogel to preserve residual hearing in adults undergoing cochlear implant surgery
Phase of Trial: Phase II
Latest Information Update: 15 Dec 2017
At a glance
- Drugs Pioglitazone (Primary)
- Indications Hearing loss
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Strekin
- 05 Dec 2017 Status changed from recruiting to completed.
- 15 Feb 2017 Accrding to Strekin media release, as of 10 Feb 2017 this trial has enrolled 50 patients in four countries and top-line data is expected in the Q4 quarter of 2017.
- 25 Nov 2015 New trial record